Nektar Therapeutics (MEX:NKTR) Other Current Liabilities: MXN90 Mil (As of Mar. 2026)


MEX:NKTR Nektar Therapeutics MEX:NKTR
47 GF Score
Price MXN1,584.15
GF Value MXN131.04
! 5 Warning Signs
View Full Analysis

What is Nektar Therapeutics Other Current Liabilities?

Nektar Therapeutics MEX:NKTR 47 Other Current Liabilities is MXN90 Mil as of Mar. 2026. GuruFocus rates MEX:NKTR with a GF Score™ of 47/100 and a GF Value™ of MXN131.04. The stock has 5 warning signs investors should review.

Nektar Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was MXN90 Mil.

Nektar Therapeutics's quarterly other current liabilities declined from Sep. 2025 (MXN158 Mil) to Dec. 2025 (MXN53 Mil) but then increased from Dec. 2025 (MXN53 Mil) to Mar. 2026 (MXN90 Mil).

Nektar Therapeutics's annual other current liabilities declined from Dec. 2023 (MXN94 Mil) to Dec. 2024 (MXN59 Mil) and declined from Dec. 2024 (MXN59 Mil) to Dec. 2025 (MXN53 Mil).

Nektar Therapeutics Other Current Liabilities Related Terms

Nektar Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Nektar Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics Other Current Liabilities Chart

Nektar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 322.79 186.81 94.26 59.06 52.94

Nektar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 102.82 123.31 157.87 52.94 90.31
MEX:NKTR
47GF Score
Nektar Therapeutics MEX:NKTR
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nektar Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of MXN90 Mil mean?
Nektar Therapeutics (MEX:NKTR) has a Other Current Liabilities of MXN90 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Nektar Therapeutics.
Is Nektar Therapeutics' Other Current Liabilities too high?
Nektar Therapeutics' current Other Current Liabilities is MXN90 Mil. Overall, Nektar Therapeutics has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' Other Current Liabilities compare to OCUL and PVLA?
Nektar Therapeutics' Other Current Liabilities of MXN90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Nektar Therapeutics. Nektar Therapeutics's current Other Current Liabilities is MXN90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Nektar Therapeutics (MEX:NKTR) has a current Other Current Liabilities of MXN90 Mil. The stock's GF Value™ is MXN131.04, compared to a current price of MXN1,584.15 — trading 1108.9% above its estimated fair value. The current Other Current Liabilities is MXN90 Mil. Nektar Therapeutics' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Nektar Therapeutics (MEX:NKTR), the current Other Current Liabilities is MXN90 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nektar Therapeutics (MEX:NKTR) Overvalued in 2026?

Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued. The current stock price of MXN1,584.15 is trading 1108.9% above its estimated GF Value™ of MXN131.04.

Key valuation signals for MEX:NKTR:

  • Other Current Liabilities: MXN90 Mil
  • GF Value™: MXN131.04 vs. price of MXN1,584.15 (1108.9% above fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the MEX:NKTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nektar Therapeutics Business Description

Other Exchanges NKTR:USA0UNL:UKITH0:Germany
Address 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
47GF Score

Get the complete analysis for MEX:NKTR

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,584.15
Price
MXN131.04
GF Value